The Food and Drug Administration (FDA) announced April 22 that it had granted licensure to expand the indication of Menactra® (sanofi pasteur) vaccine to infants as young as 9 months of age for meningococcal disease prevention. The vaccine is approved for use in individuals 9 months through 55 years of age. Even though it is the first meningococcal vaccine for infants in the US, the Advisory Committee Immunization Practices (ACIP) has yet to make an official recommendation. NCMS will publish updates from the ACIP once it makes recommendations.